Characteristics and phenotypes of cell lines
| Cell line . | Type of cell line . | Location . | CD2 . | CD3 . | CD4 . | CD8 . | HLA class I . | HLA class II . |
|---|---|---|---|---|---|---|---|---|
| SeAx | CTCL tumor cell line | Peripheral blood | +++ | + | + | − | ++ | +++ |
| MyLa 1929 | CTCL tumor cell line | Skin | ++ | + | − | + | ++ | +++ |
| MyLa 2039 | CTCL tumor cell line | Skin | ++ | − | − | − | ++ | +++ |
| MyLa 2059 | CTCL tumor cell line | Skin | ++ | − | − | − | ++ | +++ |
| MyLa 1928 | Nonmalignant T-cell line | Skin | +++ | ++ | +++ | − | ++ | +++ |
| MyLa 1850 | Nonmalignant T-cell line from CTCL patient | Skin | +++ | +++ | +++ | − | +++ | ++ |
| MySi | Nonmalignant T-cell line from CTCL patient | Skin | +++ | ++ | − | +++ | +++ | +++ |
| MyLa 2355 | Nonmalignant T-cell line from CTCL patient | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| MyLa 1885 | Nonmalignant T-cell line | Peripheral blood | +++ | ++ | +++ | − | +++ | ++ |
| MyLa 3241 | Nonmalignant T-cell line | Peripheral blood | +++ | ++ | ++ | − | +++ | ++ |
| PSOR2 | Psoriasis T-cell line | Skin | +++ | +++ | − | ++ | ++ | ++ |
| PSOR3069 | Psoriasis T-cell line | Skin | +++ | +++ | − | +++ | +++ | ++ |
| AH1 | Atopic dermatitis T-cell line | Skin | +++ | +++ | +++ | − | +++ | ++ |
| P1119 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| P1183 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| P1675 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | +++ | ++ |
| Cell line . | Type of cell line . | Location . | CD2 . | CD3 . | CD4 . | CD8 . | HLA class I . | HLA class II . |
|---|---|---|---|---|---|---|---|---|
| SeAx | CTCL tumor cell line | Peripheral blood | +++ | + | + | − | ++ | +++ |
| MyLa 1929 | CTCL tumor cell line | Skin | ++ | + | − | + | ++ | +++ |
| MyLa 2039 | CTCL tumor cell line | Skin | ++ | − | − | − | ++ | +++ |
| MyLa 2059 | CTCL tumor cell line | Skin | ++ | − | − | − | ++ | +++ |
| MyLa 1928 | Nonmalignant T-cell line | Skin | +++ | ++ | +++ | − | ++ | +++ |
| MyLa 1850 | Nonmalignant T-cell line from CTCL patient | Skin | +++ | +++ | +++ | − | +++ | ++ |
| MySi | Nonmalignant T-cell line from CTCL patient | Skin | +++ | ++ | − | +++ | +++ | +++ |
| MyLa 2355 | Nonmalignant T-cell line from CTCL patient | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| MyLa 1885 | Nonmalignant T-cell line | Peripheral blood | +++ | ++ | +++ | − | +++ | ++ |
| MyLa 3241 | Nonmalignant T-cell line | Peripheral blood | +++ | ++ | ++ | − | +++ | ++ |
| PSOR2 | Psoriasis T-cell line | Skin | +++ | +++ | − | ++ | ++ | ++ |
| PSOR3069 | Psoriasis T-cell line | Skin | +++ | +++ | − | +++ | +++ | ++ |
| AH1 | Atopic dermatitis T-cell line | Skin | +++ | +++ | +++ | − | +++ | ++ |
| P1119 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| P1183 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | − | +++ | ++ |
| P1675 | Healthy donor T-cell line | Peripheral blood | +++ | +++ | +++ | +++ | ++ |
Malignant and nonmalignant T-cell lines from skin and blood from CTCL patients, patients with inflammatory skin diseases (psoriasis and atopic dermatitis), and healthy donors were subjected to flow cytometric analysis and scored according to the relative median fluorescence intensity (MFI) of positive cells compared with nonbinding, isotype-matched control antibodies as described in “Materials and methods.” Positive scores were arbitrarily defined as high (+++ or ++++), medium (++), or low (+). Negative (−) scores were defined as less than 5% positive cells.